Core Viewpoint - The SCSP report highlights the competitive landscape between the U.S. and China in key technology sectors, indicating a complex, fluid, and uncertain multi-dimensional competition rather than a clear-cut dominance by either side [2]. Group 1: China's Strengths - China leads in four strategic technology areas: advanced batteries, advanced manufacturing, commercial drones, and 5G infrastructure, with high confidence ratings [4]. - In the battery sector, China's manufacturing capacity reached 1,705 GWh in 2023, compared to the U.S. at 93 GWh, marking an 18-fold difference. China controls 80% of global lithium-ion battery component shipments and holds about 60% of the global electric vehicle battery market [4]. - China accounts for approximately 35% of global manufacturing output, while the U.S. is at about 12%. The number of industrial robots deployed by Chinese companies in 2023 matches the total of all other countries combined [5]. - China has deployed over 4 million 5G base stations, averaging 206 per 100,000 people, compared to the U.S. with about 100,000 base stations or 77 per 100,000 people. By 2024, China is expected to have over 1 billion 5G users, covering 88% of its mobile users [5]. Group 2: U.S. Strengths - The U.S. maintains a lead in artificial intelligence, quantum computing, semiconductors, fusion energy, and internet platforms, relying on foundational research breakthroughs and private sector innovation [6]. - In AI, U.S. private investment reached $67.2 billion in 2023, compared to China's $7.76 billion, a nearly 9-fold difference. Most foundational AI models have originated from U.S. private companies [6]. - The semiconductor sector is rated as "U.S. leading, high confidence," with the CHIPS Act expected to drive over $400 billion in private investment, projecting that the U.S. will hold 28% of global advanced logic chip capacity by 2032 [7]. Group 3: Structural Weaknesses - A recurring structural pattern is observed: U.S. innovation versus Chinese commercialization. The U.S. holds 39% of global biotechnology patents but has seen a shift in the production side, with Chinese companies supplying about 17% of U.S. active pharmaceutical ingredients (APIs) [9]. - In synthetic biology, the U.S. market is valued at $16.3 billion compared to China's $1.05 billion, yet China controls 70% of global fermentation capacity, highlighting a significant production bottleneck for U.S. firms [10]. - DJI dominates the global consumer drone market with over 90% share, raising national security concerns for the U.S. as it lacks comparable domestic alternatives [10]. Group 4: Strategic Recommendations - The report suggests establishing a "Technology Competition Council" to unify strategic direction and coordinate responses across departments, addressing the misalignment between private sector focus and government priorities [11]. - The trajectory of fusion energy illustrates the competitive dynamics, with the U.S. currently leading but facing significant investment from China, which may narrow the gap in the coming years [12].

Core Insights - China plays a crucial role in the global pharmaceutical supply chain, with significant reliance from the US and other countries on Chinese production of pharmaceutical raw materials [1][2] - The US's dependency on China for active pharmaceutical ingredients (APIs) has increased dramatically, with China accounting for 45% of drug master files submitted to the FDA, surpassing India's 19% [1] - A significant portion of active ingredients used in US medications comes from a single source, with China being the exclusive supplier for at least one chemical in nearly 700 critical drugs [2] Group 1 - China has developed a large and commercialized pharmaceutical industry since the 1950s, becoming a key producer of key starting materials (KSMs) used in APIs [1] - The US's reliance on China for pharmaceutical ingredients is underscored by the fact that half of the active ingredients used in the US come from a single source [2] - The trend of dependency on a single supplier raises concerns, especially for a competitive nation like the US, although China has not threatened to halt medical product exports during trade tensions [2] Group 2 - The US government aims to establish a supply chain involving India and other allies to reduce dependency on China, but this is seen as a nearly impossible task due to low profit margins in the production of pharmaceutical raw materials [2] - A US corporate executive noted that replicating the raw material supply chain would increase costs by 50%, indicating the challenges faced by US companies in this endeavor [2] - China's dominance in many critical sectors, including pharmaceuticals, highlights the complexities of global supply chains and the difficulties in achieving "decoupling" from China [2]

Core Viewpoint - President Trump announced a 100% tariff on pharmaceutical products entering the US starting October 1st unless companies establish manufacturing plants in the US, with the EU and Japan exempt from this tariff [1] Group 1: Market Reaction - The pharmaceutical sector is responding positively to the news, with stocks of major pharmaceutical companies trading higher [2] - This tariff announcement is perceived as a "d-risking event" for the pharmaceutical industry, alleviating investor uncertainty since the initial tariff announcement on April 2nd [3] Group 2: Manufacturing Plans - Many pharmaceutical companies have already announced plans to increase manufacturing in the US, which may mitigate the impact of the tariffs [4] - A comprehensive list of companies that have made public commitments to expand manufacturing includes major players in both the US and Europe, indicating a proactive approach to the new tariff environment [5] Group 3: Future Investments - Companies in the pharmaceutical sector typically have long-term plans (5 to 10 years) for capital expenditures and manufacturing growth, which may have been accelerated due to the tariff announcement [7] - There is an expectation that new manufacturing plants will begin construction soon, reflecting a genuine commitment to increasing domestic production [8]

Core Viewpoint - Singapore's manufacturing sector continued its growth momentum in April, driven by early shipments in the electronics and aerospace engineering industries, with a year-on-year increase of 5.9% and a month-on-month increase of 5.3%, marking the tenth consecutive month of positive growth [1] Group 1: Manufacturing Performance - The manufacturing sector, excluding biomedical, saw a year-on-year growth of 8.1% in April, with the electronics sector experiencing a significant increase of 15.2% and aerospace engineering growing by 22.9% [1] - The growth in the electronics sector was primarily driven by strong export demand for communications and consumer electronics (up 67.8%), semiconductors (up 11.7%), and computer peripherals (up 11.3%) [1] - The aerospace sector was boosted by robust demand for commercial aviation maintenance, repair, and overhaul (MRO), which surged by 39.5% year-on-year [1] Group 2: Future Risks and Concerns - Despite the strong data, analysts express caution regarding future trends, noting that the current manufacturing growth is influenced by an "early shipment effect" that may not be sustainable, especially after the end of the "90-day tariff buffer window" [1] - OCBC Bank predicts that Singapore's manufacturing growth for the entire year of 2025 may only reach 0-2%, with the possibility of negative year-on-year growth in the second half of the year [2] - UOB warns that the significant growth in April was largely due to export companies rushing to ship products to avoid potential tariffs, and future trade disputes, particularly between the US and Europe, could severely impact Singapore's relevant industries [2] Group 3: Subsector Performance - Some manufacturing subsectors in Singapore showed weak performance, with biomedical manufacturing declining by 1.1%, chemicals down by 3.2%, and general manufacturing (including food, printing, and furniture) experiencing a decline of 15.2% [2] - The chemical industry faced challenges due to high inventories of refined oil and petrochemical products, compounded by raw material supply issues and maintenance activities, leading to continued output declines [2] - The biomedical sector's output was affected by changes in the product structure of active pharmaceutical ingredients (API), resulting in a year-on-year decrease in pharmaceutical output of 1.6% [2]